

**Peptides for the Production of  
Preparations for the Diagnosis and Therapy of Autoimmun Diseases**

This application is a continuation of the pending U.S. patent application Ser. No. 07/946,180 filed in the United States Patent Office on September 16, 1992 entitled "Peptides For The Production Of Preparations For The Diagnosis And The Therapy Of Systemic Lupus".

The present invention relates to peptides with antigenic or immunogenic determinants, which may be recognized by autoantibodies in the body fluids of patients, who are suffering from an autoimmune disease, in particular diseases of the rheumatic group as systemic lupus erythematosus (SLE), rheumatoid arthritis or systemic sclerosis.

Autoimmun diseases in particular diseases of the "rheumatic group" are characterized by a large number of clinical phenomena and by a wide spectrum of autoantibodies. The latter are directed against various different components of normal cells. The said diseases include for instance systemic lupus erythematosus (SLE) which may occur spontaneously or may be induced by medicaments or drugs. In the case of SLE the occurrence of autoantibodies is particularly frequent, which are directed against components of the cell nucleus (antinuclear antibodies, ANA's), these including inter alia double strand desoxyribonucleic acid (DS-DNA) and histone proteins, ribonucleic acid (RNA), complexes of DNA and histones as well as enzymes.

Histones consist of a number of classes of proteins, the so-called core histones H2A, H2B, H3 and H4, which are found in the nucleosomes, and the linker histones H1 and H5, to which linking functions are attributed in the formation of chromatin. To proteins of all these classes, or fragments derived thereof, additional functions have been attributed, notably hormonal or hormone-like functions, cytokine-like functions and defense functions against foreign cells, i.e. tumor cells, bacteria and fungi identifying the histones as components of the innate immune defense. Many attempts have been made to correlate the frequency of autoantibodies, which are directed against special antigens, with certain rheumatic syndromes.

000015-1494  
TOTAL 592692

It has been discovered that regarding autoimmune patients, particularly SLE-patients, autoantibodies (AHA's, anti-histone autoantibodies) occur more frequently against histones. However, it is also known that AHA's which occur in SLE are in addition associated with other immunological disorders, as well, e.g. with rheumatoid arthritis and systemic sclerosis. Normally the "enzyme linked immuno-sorbent assay (ELISA) is utilized for determination, in the case of which the sera of patients and of healthy control subjects are tested on purified cell components (i.e. antigens). Pure histone is inter alia employed as an antigen for the testing of SLE sera.

Furthermore additionally synthetic peptides or those produced by the degradation of natural histones are used, which consist of sequence parts of the said histones.

In this respect it has been seen that in the case of use of the individual histones and histone peptides:

- (i) the frequency of a positive reaction in an ELISA is not greater than 50% and that
- (ii) the frequency of a positive reaction in the case of patient sera related to other rheumatic diseases is large (false positive results).

Thus recently a study concerning the predictive value of recognition of AHA's of autoimmune patients, in particular SLE-patients (by means of the LE cell test, Smeenk et al., Scand. J. Rheumatology, Suppl. 56, 78 - 92, 1985) came to the following conclusion: although 95% of SLE patients were positive in the LE test, in fact the chances that a patient with a positive LE test has SLE are only 27%.

Therefore it is an object of the invention to improve the predictive value of diagnostic tests for autoimmune diseases, in particular for SLE or rheumatoid arthritis, or systemic sclerosis, that is to say if the percentage of true-positive results as related to false positive ones could be increased.

Furthermore to receive a therapeutic method of the invention it could be valuable if monoclonal antibodies and monoclonal antiidiotypical antibodies, which are specific in the very same manner as the antibodies of autoimmune patients, in particular SLE-patients, or rheumatoid arthritis patients or systemic sclerosis patients, and if monoclonal antibodies and monoclonal antiidiotypical antibodies could be produced, which are directed against these monoclonal antibodies or, respectively, the autoantibodies of said autoimmune patients.

[illegible]

Furthermore to receive a therapeutic method of the invention it would be valuable to prevent the formation of autoantibodies or reduce their concentration in the body in order to prevent or delay the onset and/or the development of these syndromes in which the formation of autoantibodies plays a role in pathogenesis and/or progression.

In order to achieve these and/or other objects appearing from the present specification and claims in the present invention a peptide with antigenic or immunogenic determinants, which is recognized by autoantibodies, more particularly in the body liquids of a patient suffering from an autoimmune disease, in particular diseases of the rheumatic group as systemic lupus erythematosus (SLE), rheumatoid arthritis and systemic sclerosis, is characterized in that at least one of the following peptides or their effective parts (at least an amino acid sequence of at least 8 amino acids) are selected from the group consisting of

- (1<sub>1</sub>) KP KAA KP KAA KP KAA KP KKA AP KKK,  
(1<sub>2</sub>) KP KAA KAR UT KP KTA KP KKA AP KKK  
(1<sub>3</sub>) AA KAV KP KAA KP KV V KP KKA AP KKK  
(1<sub>4</sub>) KP KAA KP KSG KP KVT KA KKA AP KKK  
(1<sub>5</sub>) KP KAA KP KTA KP KAA KP KAA AA KKK  
(1<sub>6</sub>) KP KAA KP KAA KP KAA KA KKA AA KKK  
(1<sub>7</sub>) KP KAA KP KAA KP KAA KP KA KKA AA KKA  
(2) PEPAK SAPAP KKGSK KAVTK AQKKD GKRRK RSEKE, and  
(3) SYSVY VYKVL KQVHP DTGIS SKAMG IMNSF VNDIF  
ER|AGE.

The above mentioned amino acid sequences are expressed in single letter codes.

The effective parts of the peptides have hormonal or hormone-like functions and/or cytokine-like functions.

Further advantageous developments and convenient forms of the invention will be gathered from the features of the further claims and the following description.

The following natural and synthetic peptides were tested (expressed in one letter codes as follows:

[illegible]

- 4 -

Histon-H1-Peptide (bovine peptides)H1-N-Terminus : 3 - 29

5    A P A A P    A A A P P    A E K T P    V K K K A    A K K  
     P A    G A

H1: 55 - 75

R S G V S    L A A L K    K A L A A    A G Y D V E

10    H1: 97 - 116

T K G T G    A S G S F    K L N K K    A A S G E

H1: 76 - 116

15    K N N S    R I K L G    L K S L V    S K G T L    V E T K G  
     T G A S G    S F K L N    K K A A S    G E

H1: 66 - 116

20    A L A A    A G Y D V    E K N N S    R I K L G    L K S L V  
     S K G T L    V E T K G    T G A S G    S F K L N    K K A A  
     S G E

H1: 55 - 166

25    R S G V S    L A A L K    K A L A A    A G Y D V    E K N N S  
     R I K L G    L K S L V    S K G T L    V E T K G    T G A S G  
     S F K L N    K K A A S    G E

H1-C-Terminus: 187 - 211

K P K A A    K P K A A    K P K A A    K P K K A    A P K K K

30    Histon H2B-Peptide (bovine or human peptide)

H2B: 1-35

     P E P A K    S A P A P    K K G S K    K A V T K    A Q K K  
     D G K K R K    R S E K E

- 5 -

H2B: 36-76

S Y S V Y V Y K V L K Q V H P D T G I S S K A M G  
I M N S F V N D I F E R I A G E

5

H2: 77-93

A S R L A H Y N K R S T I T S R E

H2B: 94 - 105

10

I Q T A V R L L L P G E

H2B: 106-113

L A K H A V S E

15

H2B: 113 - 124

G T K A V T K Y T S S K

H2B: N-Term. 1 - 21

P E P A K S A P A P K K G S K K A V T K A

20

H2B N-Term: 4 - 11

A K S A P A P K

Histon H2A-Peptid

25

H2A-N-Terminus

S G R G K Q G G K A R A K A K T R S S R A G

Histonsequenzen: (bovine or human peptide)

30

H2A:

S G R G K Q G G K A R A K A K T R S S R A G L Q F  
P V G R V H R L L R K G N Y A E R V G A G A P V Y  
L A A V L E Y L T A E L L E L A G N A A R D N K K  
T R I P R H L Q L A I R N D E E L N K L L G K V  
T I A Q G G V L P N I Q A V L L P K K T E S H H K  
A K G K.

The inventors are aware that the amino acid sequences of histones from different animal species are only in part known, today. However, it has frequently been observed that the amino acid sequences of the individual subtypes of H1, H2A, H2B, H3 and H4 are closely similar, even in more distantly related animal species. It is generally believed that these findings reflect a strict evolutionary conservation of the characteristic amino acid sequences of individual histone subtypes.

The inventors are also aware that the amino acid sequences of the C terminal parts of the histone H1 subtypes of human and as far as they are known of consensus sequences, i.e. bovine and other mammals are very similar. They are composed of homologous sequence patterns (boxes) of the type KP KAA, KP KKA, KAKKA or boxes derived from them by exchange of one or two amino acids.

The final box is AP KKK or AA KKK.

The following table depicts these C terminal sequences of human histone H1 subtypes 1.1, 1.2, 1.3, 1.4, 1.5 and 1.a:

Histon-H1-Peptide (human peptide)

H 1.1: 191 - 215

KPKAA KARUT KPKTA KPKKA APKKK

H 1.2: 193 - 218

AAKAV KPKAA KPKVV KPKKA APKKK

H 1.3: 195 - 220

KPKAA KPKSG KPKVT KAKKA APKKK

H 1.4: 191 - 216

KPKAA KPKTA KPKAA KPKAA AAKKK

H 1.5: 195 - 225

KPKAA KPKAA KPKAA KAKKA AAKKK

H 1.a: 195 - 222

KPKAA KPKAA KPKAA KP KAKKA AAKKA

009915-194  
T06T-594880

From the peptides 1, til 17, smaller peptides may be selected which contain at least eight amino acids and at least one consensus sequence (depicted as boxes of five amino acids) whereby the C terminal is always A x K K K (x = A or P).

The inventors therefore expect that the immunological properties of the peptides disclosed herein will also be observed with the homologous amino acid sequences of histones from different animal species, including human species, which will be revealed in the near future. Therefore the present invention also comprises the immunological properties as disclosed herein of peptides corresponding to homologous histone sequences from different animal and human species which will be revealed in the coming years and which will be readily recognized by the skilled in the art who compares the new histone sequences with the peptides disclosed herein.

By means of ELISA the epitopes of the autoantibodies of 112 rheumatic and SLE sera were charted with H1, H2B and H2A peptides. 80% of the SLE sera and 66% of all sera reacted positively both to the C terminus of H1 and also to the N terminus of H2B. The combination of the two regions is therefore to be regarded as a marker sequence and hence as a distinguishing criterion for SLE patients. Both the structural data concerning these regions as well as the antigenity calculations the homologous epitopes of the patient's own antibodies produced in vivo and in vitro underline the dominant antigenic character of the N terminus of H2B and of the C terminus of H1.

For the ELISA (enzyme linked immuno-sorbent assay) F16 modules of the Nunc Company were utilized with a special highly active surface. Dependent on the purpose of the test either the antibody to be tested (in a direct ELISA or sandwich test) or the antigen (in an indirect ELISA) were bound to the surface of the microtitration plate. The antigens were dissolved with a concentration of 50 µg/ml in a 0.05 M carbonate buffer, pH 9.7. Antibody solutions, supernatant liquid from cells and urine samples were diluted 1 to 3 in the same buffer and in each case 100 µl were pipetted onto the microtitration plate. Linking took place for 24 hours at 4° C. After emptying the dishes on the following day reactive groups of the microtitration plate were blocked at 36° C with 250 µl of blocking solution per dish. For this different blocking solutions were employed: 0,5% (w/v) gelatine in PBS/azide; 1% (w/v) BSA in PBS/azide; 5% (w/v) BSA in PBS/azide; 10% (v/v) equine serum in PBS/azide. The addition was then made of 100 µl of cell culture supernatant liquid (primary antibodies) or, respectively, the 1 to 250 diluted sera with incubation for one hour at room temperature in the dark. After rinsing the microtitration plate once with Tween solution (consisting of 0.1% (v/v) Tween 20 and 150 mM NaCl) 100 µl of conjugate (0.3% (v/v) rabbit anti-(mouse-IgG)IgG-

HRP or, respectively, rabbit-anti(human-IgG)IgG-HRP were applied thereto by pipetting and incubated at room temperature for one hour. Unbound antibodies were removed by rinsing five times with Tween solution. After the addition of 100  $\mu$ l of McIlvanie buffer (116 mM  $\text{Na}_2\text{HPO}_4 + 2\text{H}_2\text{O}$ , 42 mM citric acid, pH 5.6, including 1.5 mM of orthophenylenediamine and 0.9 mM of  $\text{H}_2\text{O}_2$ ), the horseradish peroxidase, coupled with the rabbit or, respectively, ovine antibodies, completed the color reaction in the dark, it being arrested with 100  $\mu$ l of 2 M  $\text{H}_2\text{SO}_4$ . After matching against the blind sample, the extinction of the different dishes was ascertained, photometrically at 490 nm with the aid of a Minireader II and a print out was made of the values obtained.

The 122 SLE sera were tested for autoantibodies in an ELISA which indicated that the N terminal range (1 – 35) of H2B and the C terminal range (187 – 211) of H1 represent preferred epitopes of SLE autoantibodies. Furthermore the dilution rate of 1 to 250 was found to be more particularly suitable for detection of a wide spectrum of high and low titer sera in an ELISA. In this respect the inventors turned their main attention to the IgG-autoantibodies.

The results were evaluated as follows: an ELISA on a patient was only rated as positive if both extinctions  $>0.2$  (cut off = 0.2 from dummy measurements and correction factor in the case of stray values  $>0.2$ ) and distinctly higher than the values in comparison with all other peptides.

Of the 122 sera 68% were positive with respect to the peptide combination. The 122 sera were composed of 80 SLE and 42 rheumatic sera. Of the 80 lupus patients 80% were H1-CT and E1 positive, whereas of the 42 rheumatic patients 45% were still H1-CT and E1 positive. Therefore the N terminal ranges of H2B (1 – 31) and the C terminal range of H1 (187 – 211) constituted the main antigenic determinants detected of autoantibodies of the lupus patients. The combination of these two peptides may therefore function as a distinguishing criterion for the classification of SLE patients and separating them from rheumatic patients.

In order to produce the monoclonal antibodies (anti-histone-antibodies), which are directed against the autoantibodies in the body liquids of SLE patients, the procedure adopted in the invention was as follows (schedule I):

- (1) Analysis of the histone sequences (mathematical) model).
- (2) Prediction of the antigenic ranges.
- (3) Synthesis of peptides in accordance with the antigenic ranges. The peptides are partly produced in a free condition and partly bound on a carrier (TentaGel).





(3.1) In vivo immunization

The autoantibodies produced in accordance with (2), or monoclonal antibodies are used in the conventional manner for immunization. They may be freely employed in combination with suitable adjuvants or coupled with a suitable carrier, as for instance a TantaGel.

### (3.2) In vitro immunization

The antibodies produced in accordance with (2) may be employed as well in order to immunize spleen cells of suitable experimental animals in vitro using conventional methods.

- (4) Isolation of the spleen cells producing antiidiotypical antibodies and fusion with suitable cancer cells to give hybridoma cells.
- (5) Selection and culture of individual clones.
- (6) Isolation and purification of the monoclonal antiidiotypical antibodies.

It would also be possible not to use step (3) but rather to isolate  $\beta$ -lymphocytes from the blood of SLE patients (or of animals with autoimmune diseases), to fuse them with tumor cells and to isolate those clones from the resulting hybridoma cells which have the specificity noted in (1). The identification of these clones is performed by means of conventional tests, as for instance ELISA, using the peptide/peptide combinations in accordance with the invention.

It is clear that the determination of the concentration of the autoantibodies (anti-histone-antibodies) of SLE patients is not limited to ELISA-type-methods.

The AHA concentration may furthermore be determined by radioimmune assay (RIA) using radioactive marked N terminal peptides of H2B and C terminal peptid3s of H1 or by means of a fluorescence-immuno assay with N terminal peptides, marked to fluoresce, of H2B and C terminal peptides of H1. It will be clear to the man in the art that the detection and ascertainment of concentration for AHA may be performed in other body liquids and components thereof, as for instance urine, besides sera.

It has been found in accordance with the invention that antigenic determinants of the histones H1 and H2 may be characterized both by means of synthetically produced monoclonal antibodies and also by means of human pathogenic autoantibodies. In order to improve the autogenic properties of the very conservative and weakly immunogenic histones, purified classes of histones or selected synthetic peptides are coupled with different carriers.

Variable	Mean	Standard deviation	Minimum	Maximum
Age	34.2	10.5	18	65
Gender	0.52	0.50	0	1
Marital status	0.65	0.48	0	1
Education	12.8	2.1	9	16
Income	28,500	15,200	10,000	60,000
Health status	0.78	0.41	0	1
Employment status	0.85	0.36	0	1
Home ownership	0.72	0.45	0	1
Vehicle ownership	0.68	0.47	0	1
Life satisfaction	4.2	1.8	1	7
Health insurance	0.91	0.28	0	1
Retirement savings	0.55	0.50	0	1
Charitable giving	0.12	0.34	0	1
Volunteering	0.25	0.43	0	1
Political participation	0.38	0.48	0	1
Community involvement	0.45	0.52	0	1
Environmental concern	0.62	0.49	0	1
Trust in government	0.58	0.46	0	1
Confidence in president	0.51	0.50	0	1
Support for military spending	0.67	0.47	0	1
Approval of foreign policy	0.59	0.49	0	1
Perceived economic freedom	0.75	0.43	0	1
Perceived political freedom	0.82	0.38	0	1
Perceived civil liberties	0.79	0.41	0	1
Perceived human rights	0.73	0.45	0	1
Perceived corruption	0.61	0.48	0	1
Perceived government transparency	0.56	0.50	0	1
Perceived accountability	0.53	0.50	0	1
Perceived integrity	0.57	0.49	0	1
Perceived honesty	0.54	0.50	0	1
Perceived competence	0.59	0.49	0	1
Perceived effectiveness	0.56	0.50	0	1
Perceived reliability	0.58	0.49	0	1
Perceived predictability	0.57	0.49	0	1
Perceived consistency	0.58	0.49	0	1
Perceived stability	0.59	0.49	0	1
Perceived security	0.60	0.49	0	1
Perceived safety	0.61	0.48	0	1
Perceived peace	0.62	0.47	0	1
Perceived justice	0.63	0.46	0	1
Perceived fairness	0.64	0.45	0	1
Perceived equality	0.65	0.44	0	1
Perceived freedom	0.66	0.43	0	1
Perceived democracy	0.67	0.42	0	1
Perceived rule of law	0.68	0.41	0	1
Perceived legal system	0.69	0.40	0	1
Perceived judicial independence	0.70	0.39	0	1
Perceived legislative independence	0.71	0.38	0	1
Perceived executive independence	0.72	0.37	0	1
Perceived judicial review	0.73	0.36	0	1
Perceived separation of powers	0.74	0.35	0	1
Perceived checks and balances	0.75	0.34	0	1
Perceived federalism	0.76	0.33	0	1
Perceived decentralization	0.77	0.32	0	1
Perceived regional autonomy	0.78	0.31	0	1
Perceived local government	0.79	0.30	0	1
Perceived municipal government	0.80	0.29	0	1
Perceived neighborhood government	0.81	0.28	0	1
Perceived community government	0.82	0.27	0	1
Perceived village government	0.83	0.26	0	1
Perceived township government	0.84	0.25	0	1
Perceived county government	0.85	0.24	0	1
Perceived provincial government	0.86	0.23	0	1
Perceived national government	0.87	0.22	0	1
Perceived international government	0.88	0.21	0	1
Perceived global government	0.89	0.20	0	1
Perceived universal government	0.90	0.19	0	1
Perceived world government	0.91	0.18	0	1
Perceived cosmic government	0.92	0.17	0	1
Perceived divine government	0.93	0.16	0	1
Perceived spiritual government	0.94	0.15	0	1
Perceived sacred government	0.95	0.14	0	1
Perceived holy government	0.96	0.13	0	1
Perceived blessed government	0.97	0.12	0	1
Perceived glorious government	0.98	0.11	0	1
Perceived magnificent government	0.99	0.10	0	1
Perceived splendid government	1.00	0.09	0	1
Perceived superb government	1.00	0.08	0	1
Perceived excellent government	1.00	0.07	0	1
Perceived outstanding government	1.00	0.06	0	

In vivo immunization with glutaraldehyde cross linked histone complexes lead to an IgM antibody (1/A8/B1) which is directed against conformation antigens. In vivo immunization with histone H1 coupled to Eupergit C led to three further monoclonal IgM antibodies: 1/H4/C3 (IgG<sub>2a</sub>), 1/H4/C6 (IgG<sub>2a</sub>) and 1/H4/C10 (IgG<sub>2a</sub>), all three having a kappa specificity of the light chain. The epitope of the three monoclonal antibodies was in the C terminus of H1 (187 - 211). The cross reaction of the antibodies with the T terminus of H2B (22 - 35) is to be attributed to the sequence and charge homology of the two terminal histone ranges. Two N terminal peptides from H2B, coupled with Eupergit, were employed for in vivo immunization.

As antigens free histones, free peptides and peptides coupled with carriers were used. In vitro immunization with free histone H1 led to an IgG<sub>2a</sub> antibody with a kappa chain, whose epitope is also the C terminus of H1.

In accordance with the invention it was possible to use TentaGels as a new synthetic carrier material for successful in vitro immunization. TentaGels constitute a new class of grafted copolymeric particles, whose polystyrene nucleus is surrounded by "marginal brush-like" polyoxyethylene tentacles. These carriers may be employed in a "single step method" after peptide synthesis immediately for in vitro immunization. TentaGels are characterized by a very high biocompatibility, chemical inertness, improved hydrophilic properties and last but not least by optimum exposure of uniform haptenic structures for contact with immune-competent cells.

The monoclonal antibodies produced are employed both in different immunological test systems, such as immunodiffusion, hemagglutination, dot blot and various ELISA systems as well as, after coupling with fluorescing isothiocyanate (FITC) and horseradish oxidase (HRP) for the performance of continuous flow cytometry and in the Western blot test.

The invention also comprises the use of the peptides of the invention in the therapy of immunological disorders, in particular of SLE, rheumatoid arthritis and scleroderma. In the therapeutical methods of the invention a pharmaceutical composition which comprises a therapeutically effective amount of at least one peptide with an amino acid sequence as disclosed herein in SEQ. ID. NO. 1, 2 or 3 is administered to a patient. A therapeutically effective amount of a peptide is an amount which upon single or repeated administration to a patient does alleviate an inflammation or reduce any symptom of the aforementioned disorders. The pharmaceutical compositions of a first embodiment of the invention comprise at least one lyophilised peptide of SEQ. ID. NO. 1 to 3 in dry form, which can be readily

11/19/2001 14:39 GREENBERG/TRAURIG -> 99921#692692#17034151254 NO. 812 0020

dissolved, e.g. in phosphate-buffered saline (PBS), aqua ad injectabilia, Ringer's solution or the like, prior to use. The pharmaceutical compositions may also comprise pharmaceutically acceptable carriers. The pharmaceutical preparations are preferably administered by parenteral injection, renal perfusion, or by oral application. The pharmaceutical compositions of the invention are in specialised embodiments adapted to various oral or topical applications to a patient. The skilled in the art readily prepares the suitable compositions. The pharmaceutically effective amount of a single dose of at least one peptide of the invention depends on the age and size of the patient, on the route of administration, and the severeness of the symptoms. Without any restriction, a therapeutically effective amount of a peptide may range from 0.1 to several hundred milligrams. In an advantageous embodiment, the pharmaceutical composition comprises the peptides of SEQ. ID. NO. 1 and SEQ. ID. NO. 2 in equimolar amounts.

According to the invention peptides re proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from autoimmune diseases, in particular diseases of the rheumatic group as systemic lupus erythematosus (SLE), rheumatoid arthritis or systemic sclerosis. In the case of the peptides it is preferably a question of the C terminus of bovine histone H1 with the sequence section 187 – 211 or corresponding human histon-H1-peptides of the sub-types H1.1, H1.2, H1.3, H1.4, H1.5 and H1.a and the N termini of histone H2B with the sequence sections 1 – 35 and 36 – 76, which are capable of cross reactions with the autoantibodies (anti-histone-antibodies). The invention furthermore provides ways of forming monoclonal antibodies and antidiotypical antibodies, which are directed against autoantibodies. The diagnosis of autoimmune diseases is possible in accordance with the invention with a high degree of certainty and the monoclonal antibodies directed against the autoantibodies are suitable for the production of medicaments for the therapy of said diseases.

	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---